JP6550370B2 - 脂質レベルを低下させるロイシンおよびニコチン酸 - Google Patents

脂質レベルを低下させるロイシンおよびニコチン酸 Download PDF

Info

Publication number
JP6550370B2
JP6550370B2 JP2016502254A JP2016502254A JP6550370B2 JP 6550370 B2 JP6550370 B2 JP 6550370B2 JP 2016502254 A JP2016502254 A JP 2016502254A JP 2016502254 A JP2016502254 A JP 2016502254A JP 6550370 B2 JP6550370 B2 JP 6550370B2
Authority
JP
Japan
Prior art keywords
nicotinic acid
composition
leucine
metabolites
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516040A (ja
JP2016516040A5 (enExample
Inventor
マイケル ジメル，
マイケル ジメル，
アンチェ ブルックバウアー，
アンチェ ブルックバウアー，
Original Assignee
ニューサート サイエンシーズ， インコーポレイテッド
ニューサート サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューサート サイエンシーズ， インコーポレイテッド, ニューサート サイエンシーズ， インコーポレイテッド filed Critical ニューサート サイエンシーズ， インコーポレイテッド
Publication of JP2016516040A publication Critical patent/JP2016516040A/ja
Publication of JP2016516040A5 publication Critical patent/JP2016516040A5/ja
Application granted granted Critical
Publication of JP6550370B2 publication Critical patent/JP6550370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
JP2016502254A 2013-03-15 2014-03-13 脂質レベルを低下させるロイシンおよびニコチン酸 Expired - Fee Related JP6550370B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800363P 2013-03-15 2013-03-15
US61/800,363 2013-03-15
PCT/US2014/026816 WO2014152016A1 (en) 2013-03-15 2014-03-13 Leucine and nicotinic acid reduces lipid levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019016877A Division JP2019065049A (ja) 2013-03-15 2019-02-01 脂質レベルを低下させるロイシンおよびニコチン酸

Publications (3)

Publication Number Publication Date
JP2016516040A JP2016516040A (ja) 2016-06-02
JP2016516040A5 JP2016516040A5 (enExample) 2017-04-13
JP6550370B2 true JP6550370B2 (ja) 2019-07-24

Family

ID=51581094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502254A Expired - Fee Related JP6550370B2 (ja) 2013-03-15 2014-03-13 脂質レベルを低下させるロイシンおよびニコチン酸
JP2019016877A Pending JP2019065049A (ja) 2013-03-15 2019-02-01 脂質レベルを低下させるロイシンおよびニコチン酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019016877A Pending JP2019065049A (ja) 2013-03-15 2019-02-01 脂質レベルを低下させるロイシンおよびニコチン酸

Country Status (16)

Country Link
US (5) US9585876B2 (enExample)
EP (1) EP2968333B1 (enExample)
JP (2) JP6550370B2 (enExample)
KR (1) KR20150130455A (enExample)
CN (1) CN105228627B (enExample)
AU (1) AU2014236687A1 (enExample)
BR (1) BR112015023310A2 (enExample)
CA (1) CA2902879C (enExample)
HK (1) HK1219660A1 (enExample)
IL (1) IL240762B (enExample)
MX (1) MX2015011195A (enExample)
PH (1) PH12015502033A1 (enExample)
RU (1) RU2015143836A (enExample)
SG (1) SG11201507046UA (enExample)
WO (1) WO2014152016A1 (enExample)
ZA (4) ZA201506481B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014000419A (es) 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016049236A1 (en) * 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
ES2963057T3 (es) 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
NZ735411A (en) 2015-03-16 2021-07-30 Chromadex Inc Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2017213486A2 (es) * 2016-06-08 2017-12-14 Astudillo De La Vega Horacio Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
CA3030740C (en) * 2016-07-19 2021-11-02 Roland W. Winterfield Use of beta-hydroxy beta-methylbutyrate in combination with leucic acid for alleviating statin side effects
JP7583523B2 (ja) * 2016-10-21 2024-11-14 メタボリック・テクノロジーズ，インコーポレーテッド β－ヒドロキシ－β－メチルブチレート（ＨＭＢ）およびプロバイオティックを使用する組成物および方法
US12370159B2 (en) 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SE540582C2 (en) * 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
WO2019108878A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating childhood or teen obesity
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
WO2019133815A1 (en) * 2017-12-28 2019-07-04 Kansas State University Research Foundation Nicotinamide riboside treatments of domesticated meat animals
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN116019780B (zh) * 2021-10-26 2024-09-24 成都拂尔医药科技有限公司 一种双黄纳米颗粒及其制备与应用
EP4727544A2 (en) 2023-06-14 2026-04-22 Chromadex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
PL450187A1 (pl) * 2024-10-31 2026-05-04 Nutropharma Spółka Z Ograniczoną Odpowiedzialnością Kompleks, sposób otrzymywania kompleksu, mikropeletka zawierająca kompleks i sposób jej otrzymywania

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
CA2242646C (en) 1996-01-09 2005-10-18 Meiji Milk Products Co., Ltd. Amino acid composition
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE29724815U1 (de) 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
HUP0101890A2 (hu) 1998-05-04 2001-10-28 Andreas Johannes Kesel Monomer, oligomer és polimer knoevenagel-kondenzációs termékek
DK1083800T3 (da) 1998-06-02 2003-03-17 Biofiber Damino As Fremgangsmåde til fodring af smågrise
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
DE69915346T2 (de) 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
JP2002539127A (ja) 1999-03-08 2002-11-19 メディキュア インコーポレーテッド ビタミンｂ−６障害のためのピリドキサル類縁体
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
EP1250052A1 (en) 2000-01-25 2002-10-23 Juvenon, Inc. Nutritional supplements for aged pets
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
WO2005029242A2 (en) 2000-06-16 2005-03-31 Bodymedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
DK1345500T3 (da) 2000-12-29 2008-11-24 Martin Francis Gannon Foderprodukt til dyr
BR0207948A (pt) 2001-03-09 2004-07-27 Produits Nestel S A Soc D Composição que melhora os déficits fisiológicos relacionados com a idade e que aumenta a longevidade
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
US7091006B2 (en) 2001-11-09 2006-08-15 Dana-Farber Cancer Institute, Inc. PGC-1β, a novel PGC-1 homologue and uses therefor
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
AU2003231788B2 (en) 2002-05-17 2008-09-11 Duke University Method for treating obesity
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
DK1551282T3 (en) 2002-10-09 2016-02-22 Bodymedia Inc DEVICE FOR RECEIVING, RECEIVING, DETERMINING AND DISPLAYING PHYSIOLOGICAL AND CONTEXTUAL INFORMATION ON A HUMAN
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
WO2004082401A1 (en) 2003-03-13 2004-09-30 Red Arrow Products Co., Llc. Browning composition for application to a film for holding a food product
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
CA2516142A1 (en) 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
DK1638586T3 (da) 2003-05-14 2008-06-23 Indus Biotech Pvt Ltd Synergistisk sammensætning til behandling af diabetes mellitus
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
JP5174348B2 (ja) 2003-09-12 2013-04-03 ボディーメディア インコーポレイテッド 心臓関連状態パラメータのモニター方法及び装置
DK1987723T3 (da) 2003-11-03 2012-07-02 Hills Pet Nutrition Inc Overtrukket dyrefodersammensætning
CN1882592B (zh) 2003-11-19 2011-08-10 帝斯曼知识产权资产管理有限公司 维生素b6的制备
WO2005049006A1 (ja) 2003-11-21 2005-06-02 Ajinomoto Co., Inc. 糖尿病治療剤
DK1694137T3 (da) 2003-11-26 2009-04-27 Hills Pet Nutrition Inc Fremgangsm de til at reducere lugt af aff ring fra k ledyr
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
WO2006009769A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
WO2006001278A1 (ja) 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080004335A1 (en) 2004-11-29 2008-01-03 Kinya Takagaki Athletic Ability Enhancing Composition
AU2006206274A1 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
SI1845994T1 (sl) 2005-02-11 2009-06-30 Argenta Discovery Ltd Kombinacija metilksantinskih spojin in steroidov za zdrvljenje kroničnih respiratornih bolezni
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
US20090163476A1 (en) 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EA014643B1 (ru) 2005-05-13 2010-12-30 Нестек С.А. Способ получения растительного сырья, обогащенного глюкозамином, и растительный экстракт, обогащенный глюкозамином
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
AU2006269459B2 (en) * 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2007039367A (ja) * 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
AU2006320167C1 (en) 2005-12-02 2011-04-07 Hill's Pet Nutrition, Inc. Methods for altering stool quality and/or stool frequency
AU2007204692B2 (en) 2006-01-10 2011-06-02 Hill's Pet Nutrition, Inc. Compositions and method for promoting fat loss
CA2644046A1 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Metabolic regulators and uses thereof
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
US20090182036A1 (en) 2006-05-10 2009-07-16 Krammer-Lukas Stephanie J M Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
ES2780193T3 (es) 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
EP2114396A4 (en) 2006-12-29 2010-03-10 Salk Inst For Biological Studi METHOD FOR IMPROVING TRAINING PERFORMANCE
SG178716A1 (en) 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
US20090006457A1 (en) 2007-02-16 2009-01-01 Stivoric John M Lifeotypes
DK2124613T3 (da) 2007-02-23 2010-09-06 Hills Pet Nutrition Inc Sammensætninger og fremgangsmåder til kontrol af kæledyrs vægt
US20080233245A1 (en) 2007-03-19 2008-09-25 Lesley Joan White Liquid nutrient composition for improving performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
WO2008119070A1 (en) 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
US20080286254A1 (en) 2007-05-17 2008-11-20 Kaneka Corporation Composition comprising licorice polyphenol
WO2008153945A2 (en) 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
US20090054450A1 (en) 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
EP2170338A2 (en) 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
JP5550077B2 (ja) 2007-09-07 2014-07-16 ナイキ インターナショナル リミテッド 運動機能性を有する装着可能な装置アセンブリ
JP2011500810A (ja) 2007-10-23 2011-01-06 プレジデント アンド フェロウズ オブ ハーバード カレッジ 運動を模倣するためのｓｉｒｔ−３関連方法及び組成物
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
RU2440771C1 (ru) 2007-12-21 2012-01-27 Хилл'С Пет Ньютришн, Инк. Состав кормового продукта для домашних животных (варианты)
US8716249B2 (en) * 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
EP3352107B1 (en) 2008-03-03 2025-10-22 NIKE Innovate C.V. Interactive athletic equipment system
CN101965170B (zh) 2008-03-17 2013-06-12 宝洁公司 用户可定制的剂量体系
EP2700434A3 (en) 2008-04-02 2014-07-02 Nike International Ltd. Wearable device assembly having athletic functionality
KR20110039249A (ko) 2008-07-07 2011-04-15 모치다 세이야쿠 가부시키가이샤 지질 이상증의 개선 또는 치료약
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
EP2320889A4 (en) 2008-08-15 2016-09-21 Nestec Sa METHOD FOR INCREASING THE CHANGE OF ENERGY REPLACEMENT
WO2010065567A2 (en) 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
EP2866103B1 (en) 2009-04-26 2023-12-13 NIKE Innovate C.V. Athletic watch
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
WO2011003045A1 (en) 2009-07-01 2011-01-06 Magceutics, Inc. Slow release magnesium composition and uses thereof
RU2485800C1 (ru) 2009-07-21 2013-06-27 Хилл'С Пет Ньютришн, Инк. Система для кормления домашнего животного
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064712A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
EP2477620A1 (en) 2009-09-18 2012-07-25 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
WO2011051974A1 (en) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
WO2011082080A1 (en) 2009-12-29 2011-07-07 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
CA2785997A1 (en) 2010-01-06 2011-07-14 Nestec S.A. Dietary regimens useful for mimicking caloric restriction
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
EP2564858A4 (en) 2010-04-28 2013-10-30 Nihon Pharmaceutical Co Ltd COMPOSITION FOR THE TREATMENT OF ASTHENOPIA
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2012097064A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
MX2014000419A (es) * 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
HK1199378A1 (en) * 2011-08-19 2015-07-03 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
JP2016505023A (ja) 2013-01-15 2016-02-18 ニューサート サイエンシーズ， インコーポレイテッド 肺の状態の処置
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
AU2014238377A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
US20160213639A1 (en) 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis

Also Published As

Publication number Publication date
ZA201506481B (en) 2017-08-30
CA2902879C (en) 2023-09-26
MX2015011195A (es) 2016-03-11
ZA201805629B (en) 2019-11-27
CN105228627B (zh) 2018-07-13
KR20150130455A (ko) 2015-11-23
US20170340615A1 (en) 2017-11-30
IL240762B (en) 2018-11-29
US20170000780A1 (en) 2017-01-05
IL240762A0 (en) 2015-10-29
BR112015023310A2 (pt) 2017-07-18
US20150056274A1 (en) 2015-02-26
EP2968333A4 (en) 2016-11-02
ZA201705790B (en) 2018-12-19
JP2016516040A (ja) 2016-06-02
EP2968333A1 (en) 2016-01-20
US9895357B2 (en) 2018-02-20
AU2014236687A1 (en) 2015-09-10
PH12015502033A1 (en) 2016-01-18
SG11201507046UA (en) 2015-10-29
US20160008329A1 (en) 2016-01-14
RU2015143836A (ru) 2017-04-27
US9585876B2 (en) 2017-03-07
ZA201606052B (en) 2018-05-30
US20180214421A1 (en) 2018-08-02
HK1219660A1 (zh) 2017-04-13
US9408834B2 (en) 2016-08-09
JP2019065049A (ja) 2019-04-25
CA2902879A1 (en) 2014-09-25
CN105228627A (zh) 2016-01-06
US9707213B2 (en) 2017-07-18
EP2968333B1 (en) 2022-01-12
WO2014152016A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
US9895357B2 (en) Compositions, methods and kits for reducing lipid levels
US20180235917A1 (en) Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
CN106456997B (zh) 用于减少或预防肝性脂肪变性的组合物和方法
CN105101958B (zh) 治疗肺病状
TW202015664A (zh) 用於治療肝疾病及失調之組合物及方法
CN109090611A (zh) 一种AGEs抑制组合物及其应用、制备方法、制剂
Fukumitsu et al. Maslinic acid in olive fruit alleviates mild knee joint pain and improves quality of life by promoting weight loss in the elderly
US20260076986A1 (en) A combination of scyllo-inositol and flavones
US20220409647A1 (en) Compositions, methods and kits for altering adipocytes
Bilder et al. Over-the-counter medications, vitamins, minerals, biologicals, and herbal supplements
RU2189243C1 (ru) Композиции "гинрозин", обладающие общеукрепляющим и адаптогенным действием
Bilal et al. Development of herbal formulation of medicinal plants and determination of its antihyperuricemic potential in vitro and in vivo rat's model.
Tafti et al. Efficacy of herbal supplementation of purslane freeze-dried juice for weight loss: An 8-week randomized, double-blind, placebo-controlled clinical trial
Abd Alkareem et al. Metformin and Omega 3 effect on Cholesterol and HDL level in Iraqi women with Poly Cystic Ovary Syndrome
WO2026047693A1 (en) Synergistic nutraceutical composition to improve cardio-metabolic health
WO2025254861A1 (en) A combination of scyllo-inositol and n-acetyl cysteine and related compounds
JP2006104080A (ja) 痛風と尿酸による血流障害の予防又は治療効果のある組成物及び健康食品。
Mullaicharam et al. EVIDENCE-BASED PRACTICE OF GINKGO BILOBA IN BRAIN HEALTH: AREVIEW
SA519401236B1 (ar) تركيبة صلبة مع ابتلاع سريع وتسهيل في البلع في شكل جسيمات صلبة غير متكتلة تشمل نوعين مختلفين من الجسيمات
CN109152805A (zh) 用于治疗和预防类风湿性关节炎的组合物
Marihal Preparation and evaluation of chewable tablet used as a nutraceutical for osteoarthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190701

R150 Certificate of patent or registration of utility model

Ref document number: 6550370

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees